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ABSTRACT 
 
Chronic  kidney  disease is  one  of the  major  health  problems  
worldwide  and a major cause of morbidity and mortality. CKD is diagnosed 
on the basis of presence of markers  of kidney damage and kidney function. 
This study was done to assess  the  prevalence  hematological  abnormalities  
in  CKD (stage3-5)  and to assess their correlation among  various  etiologies  
of  ckd(diabetes,chronic glomerulonephritis,hypertension). 
 
The  study  was  done  in 150  cases  diagnosed  as  CKD  in  the  
Department  of Nephrology, IMCU, and  in medical  ward  at tirunelveli  
Medical College Hospital. The diagnosis  was  based  on  estimated  GFR 
level <60ml/mt/1.73M2. 
 
Total count, differential count, Hb, MCV, MCH, MCHC,WBC count, 
platelet count  and peripheral smear examination, coagulation  profile  were 
done on all the patients  and results  were  compared and correlated with 
each other. 
 
Key Words :- Chronic Kidney Disease, Glomerular filtration rate, 
Anemia, Hemoglobin, White Blood Cell, leucocytes, 
Hemostasis, Platelet abnormalities.   
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INTRODUCTION 
 
Chronic kidney disease   has been a major public health problem.   
The hallmark of CKD is structural and/or functional damage of the   
glomeruli of the kidney. The most important result of   renal damage are 
loss of renal function and cardiovascular disease leading to premature 
death. CKD is a progressive condition and with the progress of the 
disease the outcomes also progress to ultimately end up with kidney 
failure.      
 
Earlier stages of  CKD can be detected through laboratory testing. 
Accumulating  evidence   in the  past 3  decades  indicates  that  the  
identification  of  CKD  in  earlier  stages  can  prevent  its progression  
and  delay  the onset and progression of  its  outcomes.  
 
There  have been discrepancies worldwide regarding the definition, 
classification and laboratory testing  of CKD resulting in lack of 
uniformity. In 2012, the National Kidney Foundation (NKF) and the 
Dialysis Outcomes Quality Initiative (DOQI) advisory board  has  
approved  the   clinical practice  guidelines to define the chronic kidney 
disease and  stage  CKD.1 
 
The  work  group  developed  the  following operational  definition  
for  chronic kidney disease (1)  renal  damage  for  ≥  3  months  as  
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defined  by  structural  or  functional abnormalities  of  the  kidney,  with  
or  without  decreased  glomerular  filtration  rate (GFR), manifest  by  
either  pathological  abnormalities or  markers  of  kidney  damage,  or 
abnormalities in imaging tests.  
 
(2) GFR less than 60ml/min/1.73m2 for ≥ 3 months with or without  
kidney damage. 
 
CKD is not a static condition.  It  tends  to  progress  and  worsen  
over  time  to ultimately end up with kidney failure because of the 
progress of the disease There are certain risk factors which  alter  the 
initiation  and progress  of  CKD and its outcomes in an adverse manner. 
 
Risk factors which  can  alter the onset and  progress of  CKD and its 
outcomes in an adverse manner; 
• Age>65  yrs,  
• Diabetes  type 1 & 2, 
• Hypertension. 
• Atherosclerosis. 
• Family  history  of  renal  disease 
• Autoimmume  disease. 
• systemic  infections. 
• urinary tract  infections/stones/obstruction. 
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• Medications (NSAIDS) 
• Drug abusers  (cocaine,heroin). 
• Neoplasia. 
• low  birth weight, reduced  kidney  mass. 
 
Identification  of  the  presence  of  risk  factors  and  institution  of  
appropriate  therapeutic interventions in the early stages of CKD are 
effective in slowing the onset and progression of  CKD.  
 
CKD is also associated with certain complications the most 
important of which are anemia, hypertension, neuropathy and nutritional 
imbalance. 
 
Anemia is a common co-morbid  finding in kidney failure patients. 
The patients with anemia in  chronic  kidney  disease  most  frequently  
present  with  complaints  pertaining  to  compromised renal functions. A 
patient with chronic kidney disease is said to besuffering   from anemia  if  
the hemoglobin  concentration is <13g/dl in adult males and  if  the Hb is 
<12g/dl  in adult females2. 
 
This level of Hb are reached when the GFR is reduced to <30%  of  
the normal value which corresponds to the serum creatinine  level of 2-
4mg/dl . Irrespective  of  the  type  of  CKD  anemia can develop. Only in 
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two conditions viz. polycystic kidney disease  and  hypertension  usually  
anemia does not develop 3. 
 
The  different  morphological  types  of  anemia  occurs  in  CKD.   
Normocytic normochromic   type which is the most common followed by 
normocytic hypochromic type   and microcytic  hypochromic type which 
is the least common.   While  anemia  being  a most common  finding  in  
CKD   patients,  leucopenia  and  thrombocytopenia  worsens  as  ckd  
stage progresses. This is probably because of inhibition of erythropoiesis, 
granulopoiesis and megakaryopoiesis, by the uremic inhibitors.  
Morphology of white blood cells    appears within normal limits   But 
clinically the patients present with an increased incidence of infections in 
uremia due to abnormal chemotactic  function and defective receptor 
regulation4. 
 
Also  qualitative    platelet  defect  occurs. There is decreased 
platelet adhesiveness and  aggregation  in  response  to  adenosine  
diphosphate   and  decreased  release  of platelet factor III, due to the 
accumulation of toxic metabolites in uremia 5. 
 
The present study is an attempt at comprehensive review of red 
blood cells (RBCs), leucocytes, platelets  &  coagualation profile and to 
assess their significance in CKD. 
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OBJECTIVES 
 
(1) To study the prevalence of hematological abnormalities in various  
stages  of  chronic kidney diseases(stage3-5). 
(2) Their  correlation among  various  etiologies of CKD (DM/chronic  
glomerulonephritis/hypertension) 
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REVIEW OF LITERATURE 
General: 
Chronic  kidney  disease  is  one  among  the significant  reasons 
for  morbidity  and  mortality   world wide6. Kidney diseases is ranked - 
3rd amongst life threatening disease in India, after malignancy and heart 
disease. About 100,000 persons go into terminal kidney failure every 
year.  
 
  Chronic kidney disease is a condition characterized by progressive 
and irreversible deterioration of renal function due to slow destruction of 
renal parenchyma, eventually terminating in death when sufficient 
numbers  of  nephrons  have been damaged. 
 
The  clinician caring for a patient with  CKD  must  first  
differentiate  whether  the  renal  insufficiency  is  acute  or  chronic.  
 
The  initial  differential  diagnostic  approach  to  chronic  renal  
insufficiency  consists  of  ascertaining  whether  the  individual   has  
glomerular  leison or  interstitial  leison  or  vascular  pathology  on  the  
basis  of  careful history  taking,  urine  analysis  and  measurement  of  
24  hour  protein  excretion.     Further refinement of  diagnostic 
considerations  requires  imaging  of  urinary  system, serologic studies, 
and renal biopsy.   
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Management  begins  with    identification  and  rectification  of  all  
acute  reversible  causes  of  renal  insufficiency  in  cases  with  CKD.  
Once  the  therapeutic options  are  in  place,  it  is  neccesary  to  
anticipate  and  treat  varied  manifestations  of  CKD .  
 
DEFINITION OF CHRONIC KIDNEY DISEASE : 
1.The work group of  DOQI  advisory board  included  situations  
that affect the kidney with  ability  to cause either  progressive  loss  of 
renal  function and complications  resulting  from  decreased  kidney  
function. 
 
  CKD  was  thus  defined  as presence  of  kidney  damage  or  
reduced  level of  kidney    function  for  three  months  or  more  
irrespective of the diagnosis. 
 
Chronic  kidney  disease  is  defined  as 
(1) Kidney damage 7  for 3 months or more, as defined by structural or 
functional abnormalities of the kidney, with or without  reduced  GFR, 
manifested by either: 
(a) Pathological abnormalities detected by histopathological  studies; or 
(b)Markers of kidney damage, including  abnormalities in the 
composition  of   blood or urine, or abnormalities in imaging  studies. 
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(2) GFR  less than 60ml / min /1.73m2 for 3 months or more, with or 
without kidney damage. 
 
The detection and classification of CKD is dependant on the 
evaluation of   markers of renal  function and markers of  renal damage. 
 
The best accepted measure of kidney function is GFR. Kidney 
damage may or may not be associated with decreased kidney function. 
Cases with renal damage are at an elevated   risk  of  loss  of  renal  
function. The explanation for GFR to be normal in spite of kidney 
damage is as follows.GFR is the product of the number of nephrons 8. 
 
So, the decline in GFR depends upon the number of  nephrons and 
the extent to which each nephron is affected. In the initial stages of 
kidney damage, when only a few glomeruli are damaged, GFR is 
maintained  because of adaptive  elevations  in glomerular capillary blood 
flow and pressure  and  due to an increased tubular  secretion  of  
metabolites   in  response  to  reduced   ultra  filtration  coefficient  and 
decreased  number of nephrons 9. But in later stages, when more  and 
more  glomeruli are damaged, it results in a decline in GFR and the 
decline progresses as the kidney damage worsens, to end with kidney 
failure. 
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The second criterion for the diagnosis of CKD is GFR <60ml / min 
/ 1.73m2  with or without kidney damage. GFR  could  be  reduced  in 
spite  of  absence of  kidney damage  in  infants  and  older  adults,  
vegetarians,  single kidney,  hypovolemia,  heart  failure,  cirrhosis10. The  
rationale  for  this  level  of  GFR  is  that   reduction in kidney function to 
this level represents  loss of  half or more of  the adult  level of  normal 
kidney  function11  and that range of normal GFR levels vary widely, as 
explained later.   
 
CONFIRMATION OF CHRONICITY OF THE KIDNEY 
DISEASE. 
This could be achieved through the following: 
 
a. History: A long history of renal disease suggests chronicity.  absent 
previous history suggests acute renal failure. 
 
b. Kidney size as detected by ultrasonography: A small echogenic  
kidneys  < 8 cm favours the diagnosis of chronic  kidney disease, while a 
normal  sized kidneys is more in favour of acute renal failure. 
There are some conditions of  chronic  kidney disease  in which kidney 
size is within normal limits or even  increased  (>13 cm)  these are: 
• Diabetic nephropathy. 
• Renal amyloidosis 
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• Infiltration (leukaemia, lymphoma, sarcoidosis). 
• polycystic  kidney  disease. 
• HIV  nephropathy. 
• Obstructive uropathy. 
• Bilateral staghorn stone. 
 
(c). Magnitude of the increase in serum creatinine in relation to the 
presenting symptoms High serum creatinine with minimal symptoms   
favours   chronic kidney  disease, while relatively low serum creatinine 
with severe symptoms is in favour of  acute  renal disease. 
 
(d) hyperphosphataemia  and  osteodystrophy : are present more with  
chronic cases.  
(e) Anaemia  is more with chronic cases. 
 
 Staging of CKD: 
The two important outcomes of CKD are loss of kidney function 
and development of  cardiovascular  complications.  These depend upon 
the severity  of  CKD.  So it is important to stage CKD based on its 
severity and this is done on the basis of levels of GFR, as follows. 
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Stages of chronic kidney disease:12 
STAGE                    DESCRIPTION GFR(ML/MIN/1.73
M2) 
        1 Kidney damage with normal or increased GFR > 90 
        2 Kidney damage with a mild decrease in GFR   60 - 89 
        3 Moderate decrease in GFR   30 - 59 
        4 Severe decrease in GFR   15 - 30 
        5 Kidney failure   <  15 
 
In   CKD    stage  3-5, there   occurs  continous  and  permanent   
reduction  in nephron number. 
 
The  distressing  term  end-stage renal disease  (ESRD)  is  that  
stage of CKD  where  there  occurs  accumulation of  , fluid, toxins and 
electrolytes  that are normally excreted by the kidneys resulting in the 
uremic syndrome, that  culminates in  death unless the toxins are  
removed  by renal replacement therapy, such as  dialysis or kidney 
transplantation.  End-stage renal disease   corresponds to stage 5 CKD. 
 
EVALUATION  OF  MARKERS  OF  RENAL  FUNCTION 
(A)Glomerular  filtration rate:  It  has been  the  best  accepted  
measure  of  renal  function, both  in  health  and  disease.  Certain   
aspects  has  to be considered while interpreting GFR. GFR is calibrated 
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for body size.  In   young   adult   males,  the  normal  mean  GFR  is  
120-130ml/min/1.73m2. Children reach adult values by approximately 2 
years. After approximately age 20-30years, GFR  declines  with  age,  fall  
equals  to 1ml/min/1.73m2 every year. So  when one  becomes   70,  GFR  
is  70ml/min/1.73m2.  In  women  GFR  is  8%  lower  at  all  ages.  GFR 
increases in pregnancy and after high protein diet. It decreases after low 
protein diet and antihypertensive agents 8,13. For this reason, definition of 
CKD is based solely on GFR only when GFR is less than 
60ml/min/1.73m2.  If GFR  is  more than  60ml/min/1.73m2, a diagnosis 
of CKD is made only in the presence of kidney damage14 . 
 
ESTIMATION  OF  GFR : 
The   Egfr  has been accepted as  best   measure  of   kidney 
function in patients with CKD and  has replaced serum  creatinine 
measurement as the diagnostic test of choice for CKD.  
 
GFR can be directly measured   using  a variety of different assays, 
but they  are not feasible  for  widespread  use in the clinical setting. A 
variety of   different prediction equations have been developed  including 
the  MDRD  and Cockroft-Gault Formulas.  
 
Estimates  of  GFR  may be  unreliable at the extremes of age, 
muscle mass and weight, and at  eGFR  levels  above 60 ml/min/1.73m2, 
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but  it  is  a reasonably  accurate measure of   true  GFR in most patients 
with moderate or more severe CKD . Both MDRD and the Cockroft-
Gault equations are acceptable for use in the clinical setting. 
 
These equations also consider age, sex, body size and  race  
because of the variations in GFR  and  creatinine metabolism with respect 
to these factors. 
 
The   equations  used  are: 
(1)EQUATION FROM THE MODIFICATION OF DIET IN 
RENAL DISEASE STUDY. 
Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–0. 203  
Multiply by 0.742 for women  and  Multiply by 1.21 for African 
Americans. 
 
(2) COCKCROFT-GAULT   EQUATION 
Estimated creatinine clearance ml/min 
   ! "
#$  %&' (/)
 
Multiply by 0.85 for women. 
Pcr  -  Serum Creatinine concentration 
 
(3)Schwartz and Counahan-Barratt  formulae in children. Serum  
creatinine  levels  should  be  calibrated  to  the  levels  recommended  by  
those laboratories which have formulated these equations15.  
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In patients with low muscle mass  until  creatinine clearance has 
declined to  less  than  half  of  normal , serum  creatinine  will  not rise  
above the normal range. the serum creatinine concentration   doubles 
approximately,  for  every 50 percent reduction in GFR. It has been  
identified   that  since  serum  creatinine  is determined  both by kidney 
function and muscle mass, patients with normal serum  creatinine and low 
muscle mass may have significant impairment  of  kidney function. 
Patients with a serum creatinine level above the normal range but under 
2.0 mg/dL have significant kidney disease but are less likely to have 
electrolyte disturbances, anemia, or bone disease  than those  patients  
with  creatinine  level of  >2.0 mg/dL. 
 
(4) CREATININE  CLEARANCE:    using  timed  urine  samples  
is  cumbersome  and  it is  not  anyway  superior  to  the   GFR estimates  
that are  provided by prediction equations. However, it  is  useful   for  
estimation   of  GFR  in  patients   who  consume  only  vegetarian food, 
in malnutrition individuals, or after amputation and muscle  wasting16. 
 
(5) INULIN  CLEARANCE  had  been   accepted  widely  as  the 
gold standard  procedure , but  assessment of  inulin clearance  
necessitates   an  intravenous  infusion  and  timed  urine  collection  over  
a  period  of  several  hours  making  the procedure  cumbersome. 
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(B)SERUM CREATININE: 
This  is  not  an accurate  measure  of  level of  renal function. It is 
dependant  on individual being  in steady  state  and  the  ability  to  
estimate  the  average  rate  of  production  of  creatinine.  Estimates will 
be unreliable if the level of GFR is changing, if muscle mass is unusually  
high or low or if dietary creatinine intake is unusually high or low18. 
Changes in  serum  creatinine   levels  do  not correlate  linearly with 
changes in GFR. In patients with early renal impairment a  small  
increment  in serum creatinine  levels may reflect a large percent decrease 
in GFR19. SCr values corresponding to GFR ranges overlap and therefore 
cut off values for staging of CKD are  arbitrary 15. In spite of  these 
problems, SCr level is  used as a  gross indicator of kidney  function  
widely  in  clinical  medicine.  The  overall  mean  SCr  value  for  
persons  aged  12 years and older is 1.16mg/dl  in men and 0.96mg/dl in 
women. At a SCr level of 2.0mg/dl, mean GFR is less than 50% of 
normal  19. 
 
EVALUATION OF MARKERS OF KIDNEY DAMAGE: 
(1) Proteinuria: 
Proteinuria is a very early and sensitive marker of kidney damage. 
It is manifested at the very start  of  the  kidney  damage  unlike  decline  
in  GFR,  which  is  manifested  only  after substantial  kidney  damage20. 
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It  is a potential  independent  risk factor  for  progression  of  renal  
disease and independent cardiovascular  risk  factor. Proteinuria   is 
assessed using a conventional dipstick method. A first morning urine 
specimen is preferred, but random urine specimens are also acceptable.   
Proteinuria  accelerates  the  rate of  decline  of  GFR  in hypertensive, 
diabetic, as  well as in  non-diabetic  individuals. 
 
Proteinuria  includes  increased  excretion  of  total  urine  protein, 
albuminuria, increased  excretion  of  other  specific  proteins.  
Albuminuria  refers  to  only  increased  urine albumin excretion. 
Microalbuminuria refers to very small amounts of albumin. Albuminuria 
is a more specific indicator of   kidney damage in terms of glomeruli 
because proteinuria includes  proteins  from  urinary  tract  and  other  
low  molecular  weight  proteins  filtered  by normal glomeruli21. 
 
 Defined  cut  off  values  in CKD 22.   
• Proteinuria of more than 300mg/day. 
• albuminuria of more than 300mg/day. 
• microalbuminuria  of  30-300mg/day.   
 
While assessing proteinuria/albuminuria, orthostatic proteinuria / 
albuminuria should be ruled out by comparing a measurement of protein 
excretion in a overnight recumbent urine collection to a daytime upright   
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urine collection. Persistent proteinuria/albuminuria should be assessed 15.  
Sustained proteinuria  >1–2 g/24 h  is  commonly associated with 
glomerular disease.  proteinuria will  not  be identified  until  patients   
become  edematous or notice foaming of  urine on voiding.  Sustained  
proteinuria    has to be distinguished  from  benign proteinuria   in the 
normal population,which  is  nonsustained,  generally <1 g/24 h, and is 
sometimes called functional or  transient  proteinuria. Fever, exercise, 
obesity, sleep apnea, emotional stress, and congestive heart failure can 
explain transient proteinuria. Proteinuria  only seen with  upright posture  
is  called  as  orthostatic  proteinuria  and has a benign prognosis. Isolated 
proteinuria sustained over  multiple  visits is  found in diabetic 
nephropathy,   membranoproliferative  glomerulonephritis , and FSGS. 
Proteinuria  in  most adults with glomerular disease  is  nonselective, 
containing albumin and a mixture of other serum proteins23. 
 
(2) Urine sediment examination: Presence of RBCs-normal and 
dysmorphic and WBCs indicates CKD. But they are not sensitive and 
specific. They can be absent in CKD and be present in pathology of 
tubules, interstitium and urinary tract24. 
 
(3)Imaging studies: They suggest intrinsic kidney disease24. Renal  
ultrasonagraphy  helps  to establish the diagnosis and prognosis by  
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documenting the size of the kidneys. Normal  size indicates kidney 
disease that may be amenable to medical treatment. 
 
Classification of CKD by pathology and etiology25 
 
Pathology Etiology Prevalence 
Diabetic glomerulosclerosis Diabetes Mellitus 33% 
Vascular diseases Hypertension, renal artery stenosis, 
HUS 
21% 
Glomerular diseases SLE, vasculitis, amyloidosis, 
drugs, HIV                    
19% 
 
Cystic diseases Autosomal dominant or recessive 6% 
Tubulointerstitial diseases Infection, stones, NSAIDs, 
antibiotics 
4% 
                                    
HUS-Hemolytic uremic syndrome, SLE-Systemic lupus 
erythematoses,  HIV-Human immuno deficiency virus,  NSAIDs-Non 
steroidal anti inflammatory drugs. 
 
Diabetes  mellitus has  been the  commonest  etiology  for  CKD  
throughout  the  world  and  in  India 26, 27. From the table it is evident that 
apart from glomerular diseases, tubulointerstitial diseases, vascular 
diseases and cystic diseases contribute to CKD. But because  the  
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explained  markers  are  specific for glomerular  damage and not for 
tubulointerstitial  and  vascular damage, criteria are  not  standardized  for  
these  conditions.  However  the  diagnosis  of  CKD  in  these conditions 
is also based on GFR and SCr. GFR  might  be  normal  in  
tubulointerstial diseases where glomeruli is spared in the disease process, 
these cases might go undiagnosed as CKD.  
 
The diagnosis of underlying disease is by serology, 
ultrasonography and renal biopsy. The diagnosis is important as, when 
the disease progresses it worsens the kidney damage. Appropriate 
therapeutic intervention and control of the underlying disease will prevent 
the progress of CKD 26,27. 
 
As already stated, CKD is not a static condition. It  tends to 
progress and worsen over time to ultimately end up with kidney failure.  
There  are  many  risk  factors,  which  influence  this progression  and  
outcomes  of  CKD  in  an  adverse  manner. 
 
 FACTORS  WHICH  INFLUENCE  THE  PROGRESSION OF 
CKD: 
• Hypertension.  
• diabetes mellitus. 
• African  ancestry 
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• older age.  
• Autoimmune diseases. 
• Family history of  renal problem. 
•  Previous  history of acute kidney injury. 
• presence of  any  proteinuria  and  abnormal urinary sediment.  
• structural abnormalities in the urinary tract. 
•  Genetic predisposition-allelic versions of the APOL1 gene. ( focal 
segmental glomerulosclerosis).28 
 
The  extent  to  which  these factors can affect the outcomes of 
kidney damage depends on the severity of the disease and rate of 
progression29. Identification of the presence of risk factors and instituting 
appropriate therapeutic intervention in the early stages of CKD are 
effective in slowing the progression of CKD.  
 
Clinical presentation of CKD 
The  clinical  presentation  of  these  patients  will  be  
representative  of  kidney damage,  loss  of  kidney  function  and  of  the  
causative  disease  entity.  The signs and symptoms are grouped as uremic 
syndrome30 characterized by circulating uremic toxins. It is associated 
with complications in virtually all organs. 
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Stages 1 and 2 CKD  has  not  been associated with any symptoms, 
there may be symptoms from the underlying renal disease  itself,  such as 
edema in patients with nephrotic syndrome  and   signs and  symptoms  of  
hypertension  secondary  to the renal  parenchymal  disease in individuals  
even  with well-preserved GFR. When GFR declines to stages 3 and 4, all 
clinical and  laboratory complications  in  CKD become prominent. any 
organ system could  be affected. Anemia  usually  presents with  easy  
fatiguability, poor  appetite and  progressive  malnutrition, abnormalities 
in  mineral  calcium, phosphorus metabolism and  hormones, such as 
1,25(OH)2D3 (calcitriol), parathyroid harmone (PTH), and fibroblast 
growth factor 23 (FGF-23) are altered; as well are abnormalities in 
electrolytes, water, and acid-base homeostasis. 
 
Most  individuals , especially elderly aged, will have  eGFR  values  
that  are  compatible with stage  2 or 3 CKD  and  majority of these 
patients  will  show  no  further decline of renal function. when  the  
patient progresses to stage 5 CKD,  toxins begin to  accumulate , and the 
patients  start  experiencing  a marked disturbance in  their activities of 
daily living, well-being,  nutritional status, and water and electrolyte 
homeostasis, resulting   in  the  uremic  syndrome. Which  will eventually 
lead  to  death unless renal replacement therapy  like dialysis or 
transplantation has been  instituted. 
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When  a patient  presents  with  signs  and symptoms of  CKD, the  
evaluation  proceeds as    follows: 
1) Confirmation  of  the  presence  of  CKD  by assessing  markers  of   
kidney injury and markers of  reduced  kidney function. 
2) Identification  of  the  underlying  disease  leading to CKD and  
employing  appropriate  therapeutic  intervention  so as to prevent 
the disease from damaging the kidney further. 
3) Identification  of  the  presence  of  risk  factors and  employing  
measures  to  check  them, to prevent the adverse  outcomes  of  
CKD. 
4) Employment of  treatment strategies for CKD itself, depending 
upon the severity of CKD.  Early  stages  might  not  require  
intervention  but  kidney  failure  will  need  some form of 
replacement therapy. 
5) Identification  of  complications as  a  part  of  uremic  syndrome  
and  undertaking  appropriate measures to correct them. 
6) Constant   evaluation of the progress of the disease so as to have an 
idea  as to when approximately the patient will have kidney failure. 
This will help plan replacement therapies. 
 
Some  patients  with  early  stages  of  CKD  are  asymptomatic.  If  
any  individual  is known  to  suffer  from  any  of  the  diseases  known  
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to  cause  CKD,  he  should  be  under constant and periodical screening . 
The disease should be maintained at adequate control so as to prevent the 
onset of CKD.  
 
Anemia of chronic kidney disease  
Anemia  is  both  a complication of  CKD  as a part of uremic 
syndrome as  well  as risk factor, which influences the adverse outcomes  
of  CKD. So  evaluation and management of anemia is  of  prime  
importance to prevent  the progress of CKD and for the general well 
being of the patient. The erythropoietic  system  is  affected  by numerous 
ways, with the primary clinical outcome, being reduced erythrocyte  mass 
and  anemia. This complication of renal failure was first observed   by 
Richard Bright in 1836.31 
 
Anemia in   CKD  being  one of  the earliest  signs of  renal  
dysfunction,  but  because of  its insidious onset   it usually  goes 
undetected   . Anemia  usually develops  gradually when  kidney  
function  declines and the GFR has  droped   to 70 mL/min  in males and 
50 mL/min in female patients. 
 
Hemoglobin  measurement   have  been  the preferred  laboratory  
investigation  for diagnosing  anemia.  Hematocrit   can also  be  used , 
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but   it  has been  subject to measurement error  because  of  sample 
storage  and   differences  in analytic equipments. 
 
Definition and identification of anemia in CKD: Anemia  can be 
diagnosed in adults and children above 15 years  with CKD  when  the 
Hb concentration  is  less than 13.0 g/dl (130 g/l) in males and  less than 
12.0 g/dl  (120 g/l) in females. 
 
Definition of anemia, in this study   anemia was defined using  
The World Health Organization (WHO) criteria, hemoglobin 
concentration lower than 13.0 g/dl in men and lower than 12.0g/dl in non 
pregnant women. 
• hemoglobin10 - 12.9 g/dl for men and 10 -11.9 g/dl for women was 
used to define mild anemia. 
•  hemoglobin 7 - 9.9 g/dl for both genders defined moderate anemia  
•  hemoglobin < 7 g/dl for both genders defined severe anemia33. 
 
Evaluation of anemia in people with CKD: 
For identification of anemia in people with CKD, measure Hb 
concentration, 
• When indicated clinically in people with GFR more than 60 
ml/min/1.73 m2(stage 1 and 2). 
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•  Once in a year in people with GFR 30–59 ml/min/1.73 m2   
(stage 3 CKD). 
• twice  per  year in people with GFR  less than 30 ml/min/1.73m2   
( stage 4  and 5 CKD). 
 
 IMPACT OF ANEMIA IN CKD PATIENTS: 
1. Anemia  in  CKD  patients  have  been  associated with 
cardiovascular complications. Anaemia  have  been independently 
associated with the development of left ventricular hypertrophy 
(LVH), which  is an independent predictor of subsequent cardiac 
morbidity and mortality.  
2. The  presence  of  anemia  have  been  associated with a greater 
rate of  hospitalizations and mortality.  
3. CKD  patients suffering from anemia   usually  have an impaired 
quality of life, exercise capacity, cognitive and sexual function .  
4. Anemia in CKD  patients  also  have  increased  blood  transfusion  
requirements. 
 
The causes of anemia can be broadly categorized as  follows 34, 35, 36 
1. DECREASED  BONE MARROW  SYNTHESIS: 
a) bone marrow suppression as a part of uremic syndrome 32,35,36 
b) Decreased  Erythropoietin  production 34 
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c) Bone marrow fibrosis due to increased parathyroid hormone 39 
d) Inflammatory cytokines:  Increased levels of inflammatory 
cytokines  has  been found in patients with CKD, because of  
inflammation in the glomeruli   as a part of the disease  process  
causing  CKD or  because of concomitant infections in CKD. 
Inflammatory cytokines , inhibit the production of  EPO and  they  
render  erythroid cells insensitive to the action of  EPO 47 leading 
to a normocytic normochromic blood picture. Inflammation 
upregulates  hepcidin,  a protein  synthesized  in  liver  that  
reduces  gut  iron  absorption and interferes with  iron release  from  
the reticuloendothelial system to the developing erythron. 
 
2. SHORTENED RED CELL SURVIVAL:  
a) As a part of  uremic syndrome  RBC survival is decreased in 
uremic patient’s  in proportion to the blood urea nitrogen 
concentration and, it improves significantly after intensive 
hemodialysis. Increased   expression  of  phosphatidylserine  
occurs  on the outer cell surface  of  red blood cells  due  to uremic 
environment  in plasma. This enhances the recognition of damaged 
red blood cells by macrophage, leading to their subsequent 
destruction and decreased survival38 
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b) Increased osmotic fragility of RBCs due to increased  Parathyriod 
harmone37 
c) Hemolysis due to concomitant infections.  
d) Hemolysis  due to microangiopathy- primary disease 
manifestation. 
e) Dialysis   itself  can  contribute to the anemia. Iron deficiency can 
result from unavoidable  dialyzer  blood  loss, frequent blood 
sampling  and  clotted dialysis membranes. Hemolysis  will occur 
if there are problems with the dialysate  such as temperature 
problems, contamination with copper, aluminum , chloramine, 
chlorine, or fluoride. Folic acid, a water soluble vitamin  necessary  
for normal red blood cell synthesis, is dialyzable. usually, dialysis 
patients  has  to be  given ,oral  supplementation with folic acid  in 
case their  normal diet does not meet the  sufficient folate required  
to keep up with its loss through  dialysis. 
(3) Hemodilution due to fluid overload. 
(4) Iron deficiency 34   
The causes are listed below : 
• Reduced  iron absorption  due to uremic syndrome 
• Loss of  iron and  RBCs  due to bleeding tendencies in uremic 
syndrome 
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• loss of transferrin  in urine   as a part of proteinuria,  causing  
impaired  iron transport 
• Dialysis  related  loss of  RBCs and  iron 
• Blood loss due to frequent blood  sampling. 
(5) Folate and  vitamin  B12 deficiency 34 
(6) Electrolyte imbalances 40 
(7) Aluminium toxicity 34   
(8) Underlying hemoglobinopathies 40 
(9) Comorbid conditions, pregnancy, HIV,   hypo/hyperthyroidism, 
autoimmune disease.                      
(10) Bleeding tendencies. 
(11) Hypersplenism  especially  in  multiple  transfused  patient.  
(12) Immunosuppressive  drug  especially mycophenolate  
mofetil,tacrolimus, sirolimus  intake  is associated  with  low  
hematocrit. 
 
 Anemia in azotemia as a part of uremic syndrome  35, 36. 
Uremic syndrome is characterized by circulating toxins which 
accumulate in blood due to decreased excretion by the diseased kidney 
35,32, 36,38
 These toxins have deleterious effects on many organ systems.  
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The circulating toxins are: 
a) Toxic products of protein  metabolism-urea, guanidino containing 
compounds37. 
b) Advanced oxidation products 
c) Products of bacterial metabolism 
d) Homocysteine 
e) Electrolytes 37 
f) Metabolic acidosis 37 
g) Polyamines -spermine and spermidine36. 
 
These  circulating  toxins,  specifically  suppress  the  erythroid  
series  in  the  bone marrow. There is a decrease in the  erythroid   
mitoses . The arrest is in the erythroblastic stage, resulting in  the  
formation  of   very few younger forms of the series. These toxins inhibit 
erythroid  cells  in  a  non specific  way.  
 
They do render these cells insensitive to the action of 
erythropoietin, a hormone secreted by  kidney  which  is  responsible  for  
the  maintenance  of  normal  erythropoiesis32. Erythropoietin  is the 
hormone  which  has been  the major  humoral regulator of   red cell 
synthesis  and  helps  in maintaining the  RBC viability , by retarding the 
cleavage of DNA that occurs  normally in  colony  forming  unit-
erythroid.  In  the  absence of  EPO, DNA cleavage is rapid and leads to 
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cell death.  This probably  explains  the  selective  suppression  of  
erythroid  cells  by  uremic  toxins.  This is reflected in the peripheral 
blood picture as a normocytic normochromic anemia.  
 
This is the most common type of anemia in CKD. The Hb, RBC 
count and Hct decrease but the mean corpuscular volume (MCV), the 
mean corpuscular hemoglobin content and concentration (MCH and 
MCHC) respectively remain unaltered. 
 
The anemia of CKD  have a  number of adverse  pathophysiologic 
consequences, including reduced  oxygen  delivery to  tissues and  
utilization, increased cardiac output, ventricular dilation and hypertrophy.  
Clinically   presents  with  easy fatiguability  and  reduced  exercise 
tolerance, angina, cardiac  failure, diminished  intelligence  and mental  
acuity, and impaired  host  defenses  against infection.  Also, anemia may 
play a role in growth retardation in children with CKD. While many 
studies in CKD patients have found that anemia and resistance to 
exogenous EPO are associated with a poor prognosis, the relative 
contribution to a poor outcome is by low hematocrit itself. 
 
Abnormalities of leukocytes 
The   abnormalities with  respect  to  leukocytes  are  qualitative,  
they being  functionally defective.  Granulocytes  show  impaired  
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migration  and  abnormal  chemotactic activity. Macrophage Fcγ receptor 
is impaired4.  Functional  effects on  cell mediated  immunity  has  been  
demonstrated by  depressed  delayed type hypersensitivity ,this leads to 
increased incidence of infections in spite of increased levels  of  
leukocytes. also reduction  in natural  killer  cells  occur  There may  be  
lymphopenia. The Na+kATPase is defective in leukocyte membrane 
leading to loss of leukocytes41 .Inflammation is a major pathogenetic 
factor  in chronic kidney  disease. Inflammation  mediates  influx of  
monocytes , macrophage  proliferation and matrix expansion,  resulting  
in glomerulosclerosis  and  tubulointerstitial injury  which  will further 
exacerbate  renal  injuries. white blood cell  count  has  been   a 
traditional   marker  of  inflammation  and  infection  responses, and 
former  studies have  showed  that  their  have  been  a significant 
association of  WBC count and  poor  outcome  in dialysis patients. In  
Atherosclerosis Risks in Communities (ARIC) study,  it  has  been 
showed that  increased  WBC count   is  correlated with greater risk for 
renal  function deteriotation , but  Kovesdy et.al study  revealed the 
opposite observation. 
 
Inflammation in  chronic kidney disease  patients  is  due  to: 
• Poor  appetite  leading to  malnutrition. 
•  Infection  of  dialysis vascular access.  
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• Periodontal  infections. 
• Foot  ulcers. 
• Anemia. 
• Uremic  toxins. 
• A transplanted kidney  that no longer works 
 
There is a relation between malnutrition and chronic inflammation 
in patients with ckd. Poor  appetite  leads  to  low  calorie  and  protein  
intake  and over a period of time  protein energy  malnutrition  results.  
ultimately culminating  in weight loss and  muscle  wasting.   
inflammation interferes with the body’s ability to make new proteins, 
leading to  muscle  wasting.In  a person  with  inflammation, cytokines 
are released. Normally cytokines  help to  defence  against infection. but, 
cytokines  also reduce the appetite  and  slow down  gastric emptying.  If 
chronic inflammation is not treated, cytokines  contribute to chronic low  
albumin levels and muscle  wasting . hypoalbuminemia  is used as a 
marker  for  malnutrition and inflammation in  kidney disease patients . 
they  have  poor quality of life, low hemoglobin levels and  increased  
hospitalizations.  
 
Patients with CKD  have  more  spikes in  leukocyte counts  than  
their non-CKD counterparts. These spikes  are  between 1.5- and 3.0-fold  
higher in those with CKD.  Spikes  in  absolute  and  percent  eosinophil 
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count  and  percent granulocyte and percent monocyte counts  are  
independent  risk factors  for the combined  endpoint  of  all-cause 
mortality and ESRD. Granulocyte  and  monocyte  spikes  were  
independently  associated with  ESRD  and  death  in  this population. 
Thus, inflammatory events , among  patients with CKD  have  significant   
prognostic importance. Inflammatory events were associated with an 
increased risk of ESRD and death. These  inflammatory  events  also  
includes   those  confined to the kidney, which  may  accelerate  the  
decline in renal function. Many  recent  studies ,  have  increasingly  
reported  prominent  clusters  of  inflammatory cells, particularly 
macrophages, in renal biopsy specimens from patients with diabetic 
nephropathy . Peritubular macrophages and  granulocytes  were  inversely  
correlated  with  estimated  GFR at the time of  biopsy. However, 
clinically it is perhaps  more  likely  that these inflammatory events   also 
included  inflammatory  illnesses  such  as  pneumonia,  bacteremia, and  
urinary tract infections. Such illnesses  are  associated  with  volume 
depletion  and nephrotoxin  exposure and perhaps induce an 
inflammatory response in the kidney, factors  that  may have caused an 
accelerated time to ESRD and/or death. Others  have  reported  an  
increased  risk  of mortality  with  neutrophil count  among  hemodialysis  
patients.  
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Spikes in  eosinophil counts  were  also  associated with  
ESRD/death  outcomes. eosinophilic spikes may  be  due  to  subclinical   
atheroembolic   events or allergic  responses  to environmental antigens  
or drug exposures. Another suggested possibility is that of deficiency or 
resistance to cortisol. Studies have described that their is relationship 
between stress and hypercortisolemia and eosinopenia. In those with 
corticosteroid deficiency, eosinophilia may be seen. Patients with CKD 
may have resistance to cortisol and eosinophilia. In a recent cross-
sectional study, eosinophilia was associated with albuminuria .  Kovesdy 
et al., who have reported among CKD veterans not on dialysis an inverse 
relationship between lymphocyte count and all-cause mortality. Similarly, 
low lymphocyte counts are associated with mortality among hemodialysis 
patients.  
 
Effect of dialysis on leukocytes:  Hemodialysis   leads to transient 
neutropenia within 2 hours after initiation of dialysis due to the   
sequestration of granulocytes in the dialysis apparatus.  It  also  leads  to  
loss  of inflammatory  cytokines  in  the  permeable biocompatible  
membrane  resulting  in  impaired immunity. 
 
Continous Ambulatory Peritoneal Dialysis suppresses  inflammatory 
cells and  has  cytotoxic effect  on  mesothelial cells leading  to  impaired  
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cellular  defense  mechanism  against  bacterial  peritonitis.  The dialysis 
fluids are the culprits42. 
 
PLATELETS AND HEMOSTASIS IN CKD 6  
Patients in advanced stages of CKD may have a reduced platelet 
factor III activity, abnormal platelet aggregation and adhesiveness, and 
impaired prothrombin consumption and prolonged bleeding time. Clinical  
presentations include an  increased  bleeding tendency  and bruising,  
menorrhagia, haematemesis and malena  from spontaneous GI bleeding, 
prolonged bleeding  from  surgical incisions. 
 
Also, CKD patients  have a  increased  tendency  for  
thromboembolism, usually  if  they have  renal problem  that includes 
nephrotic-range proteinuria  which  results in hypoalbuminemia and renal 
loss of anticoagulant factors  leading  to a thrombophilic state. 
 
ABNORMALITIES OF PLATELETS: 
In CKD, impaired   erythropoietin secretion leads to a decrease in 
platelet count.  Receptors for erythropoietin has been detected in 
megakaryocytes and because of extensive homology between 
erythropoietin and thrombopoietin, erythropoietin   also act as the major 
humoral regulator of platelet mass. Erythropoietin  potentiates  the  action  
of megakaryocyte  colony stimulating  factors,  acetlyhydroase  (PAF-
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AH) and  paraoxonase  (PON1)43.  In patients with chronic kidney disease 
treated with erythropoietin, a small increase in platelet count, averaging 
approximately 30,000 per microliter has been noted. Platelet dysfunction 
is the most consistent and important feature. Dialyzable substances like 
urea, creatinine, guanidinosuccinic acid, phenol which accumalates in 
uremia causes impairment of platelet aggregation.   But dialysis does not 
correct prolonged BT. Bleeding diathesis   usually disappears after renal 
transplantation. 
 
Also   following qualitative   platelet   abnormalities have been observed: 
• Decreased platelet factor III release. 
• Decreased   platelet adhesiveness and aggregation in response to 
adenosine di phosphate. 
• Storage pool defect and decreased dense granule  content.  
• Defective   arachidonic  acid   metabolism and decreased  release  
of  endogenous  arachidonic  acid  from  platelet phospholipids  
leading to decreased production  of thromboxane A2 which  is  
the  main abnormality. 
• Decreased   IIb-IIIa receptors on platelets5.   
• Reduced sensitivity to platelet agonists. 
• Abnormal  expression  of  platelet  glycoproteins  and 
•  Depressed prostaglandin metabolism.  
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CAUSES FOR PLATELET DYSFUNCTION: 
 Uremic toxins:- Inhibitors  of  low  molecular  weight  which  
are guanidine succinic  acid,  phenolic  acids,  urea  or  a  
combination  of  these.   
 Low hemoglobin levels. 
 Increased nitric oxide production. 
 Abnormalities in Von Willebrand factor. 
 Use of medications like non-steroidal anti-inflammatory drugs, 
aspirin, and β-lactam antibiotics.  
 
HEMOSTATIC ABNORMALITIES IN CKD:44  
The balance between coagulation and   anti-coagulation is altered 
in chronic kidney disease.  Initial  stages  of  chronic kidney disease  are  
usually  associated  with  prothrombotic tendencies , whereas  in its more  
later  stage  patients  also suffer from a bleeding  tendencies.          
              
Bleeding tendencies: 
Patients   with CKD have bleeding tendency which is manifested 
by ecchymoses, purpurae, epitaxis, prolonged bleeding from venipunture 
sites. In his Epistola Anatomica-medica XLI, the Italian anatomist and 
pathologist Giambattisa Morgagni  (1682-1771) described a woman with 
severe bleeding (epistaxis and hematemesis) who had the odour of urine 
on her breath. This is probably the first description of association of 
                                 
 
38 
 
uremia and bleeding tendency. Because of the introduction of dialysis, 
bleeding in uremia is more easily controlled. However the underlying 
bleeding diathesis remains. 
 
 Following  are reasons;  
• Thrombocytopathy. 
• Thrombocytopenia. 
• Anemia. 
• Increased activated  protein  c. 
• Defective  structure and  distribution of  von Willebrand factor  
leading to poor platelet aggregation. 
• Deficiency of factors II, VI, IX, XII, XIII   as they are  lost in 
urine. 
• Dysfibrinogenemia  are  the  factors  which  lead  to  a  bleeding  
tendency  in  uremia. 
 
Bleeding time being a universal test which  is measured by making 
a small incision on the upper arm, earlobe, finger, or thigh and normally 
is between 1 and 7 minutes. The characteristic laboratory finding is a 
prolonged bleeding  time  longer than 8 minutes. BT is the best predictor 
of uraemic  bleeding, but  suffers from poor reproducibility and 
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accuracy44. Alternative in vitro test to replicate BT has not been 
identified. 
 
Treatment  regimens like  cryoprecipitate  and  DDAVP are used in 
emergent situations.when immediate  action  is unnecessary conjugated 
oestrogens and  initiation  of  dialysis  are  appropriate. 
 
Thrombotic tendencies: 
In  addition to increased  bleeding risk,  a  variety of thrombotic 
complications  has  been  observed in patients with chronic renal failure, 
including  coronary  artery  disease, cerebrovascular disease, peripheral 
vascular disease and  cardiac failure. Already in mild to moderate chronic 
kidney disease an increased  risk for  cardiovascular disease  and slightly  
higher  mortality have been reported.  
 
PROCOAGUALANT  FACTORS:  
• Increased   tissue  factor                                                                                                   
• increased  von-wille brand  factor, factor12a, factor 7a,  
• increased  plasminogen  activator  inhibitor. 
• reduced  tissue  plasminogen activator.        
 
• Abnormalities of platelets-  Platelets  can also  be hyper aggregable 
due to increased plasma  thromboglobulin  and  increased 
prostaglandin due to increased hepatic secretion as a part of  
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compensatory mechanism for hypoalbuminemia. Also  decrease in 
platelet count in patients with chronic renal disease leads to prolonged 
bleeding time and altered haemostasis.43 
• Abnormalities of clotting factors: Decreased  protein  c  and  
antithrombin III  as  they are  lost  in  urine,  decreased fibrinolytic  
activity  and  increased  concentration  of  factors  II,  V,  VII,  VIII,  
X,  XIII  due  to increased  hepatic   synthesis  as  a  part  of  
compensation  for  hypoalbuminemia  are  the  factors  responsible for  
rendering  a  thrombotic  state  in patients  with uremia.  Thrombotic  
tendency  is a known complication  in  patients on treatment  with 
recombitant erythropoietin. 
 
HEMATOLOGICAL   ABNORMALITIES  IN CKD AND  THEIR  
CORELATION WITH  VARIOUS ETIOLOGIES  
ANEMIA AND DIABETES: 
Anemia  is a  most common complication of diabetic nephropathy.  
It have  been recognised  that   in diabetic  individuals  anemia is seen not 
only in advanced  renal failure, but also frequently in patients  with only  
minor derangements  of renal function. At any level of GFR anemia  is 
more frequent  and severe in diabetic compared to nondiabetic patients.45 
anemia  is  a  risk factor  which  neccesiates  renal replacement therapy  
in diabetes . In addition,  a  lower Hb  have  been  associated with a more  
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a rapid decline in the GFR  and  it is a  significant  negative  predictor  of  
end stage  renal  disease.  Furthermore, treating  anemia early in renal 
failure have  been demonstrated  to  slow  the rate of decline of renal 
function.  Anemia  also have  a negative impact  on patient’s survival, and 
is considered to be an important  cardiovascular risk factor  associated 
with renal disease.46 
 
 Reasons for the earlier onset of anemia in patients with diabetes 
• Severe  symptomatic  autonomic neuropathy, causing  efferent 
sympathetic denervation of  the kidney leading to  loss of  appropriate 
erythropoietin  secretion. 
• inhibition of  EPO  release.  inappropriate response of erythropoietin 
to anaemia. interstitial  fibrosis is  associated  with  impaired function 
of  EPO-producing fibroblasts   and  autonomic neuropathy is  
associated with  a defect of “anemia-sensing” mechanisms and   both 
may  contribute to EPO deficiency. 
• damage to the renal interstitium. 
• systemic inflammation. 
• Iron deficiency.   
• Iatrogenic factors, e.g. ACE  inhibitor  treatment.46 
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HYPERTENSIVE  NEPHROSCLEROSIS:   Hypertension frequently  
accompanies advancing  CKD, and  it  is often  assumed as the cause 
rather  than the  effect of CKD. In fact, more  patients  develop  
hypertension  from CKD  than  develop CKD from hypertension , 
ie,hypertensive nephrosclerosis. Hypertension  exacerbates  proteinuria 
and promotes tubulointerstitial inflammation,  fibrosis, and tubular 
atrophy, further elevating BP. Some   studies  have  shown  that   in ckd  
due  to  hypertension , anemia  occurs  only  in  very  advanced  stages. 
 
AUTOSOMAL  DOMINANT POLYCYSTIC  KIDNEY  DISEASE:  
This  is a  common  inherited  kidney disorder. In this condition  
fluid-filled cysts  develop in the kidneys. Patients become  symptomatic   
later in life,  usually  between the  ages of 30 and 40. However, symptoms  
can  also start  in childhood.  PKD  may  impair  kidney function and lead  
to kidney failure.  PKD   had   higher levels of  haemoglobin and EPO. 
Anemia is usually  less  common  than  in  other types of chronic  kidney 
disease, probably because erythropoietin  production  is preserved. This  
is true with initial  stages, but  as  CKD  progresses  anemia  ensues. PKD  
is characterized by numerous cysts. With age, the cysts will increase in 
both size and number.The large cysts will compress the adjacent kidney 
tissues and replace more healthy tissues,thus leading to progressive renal 
function decline. Healthy kidneys can produce erythropoietin (EPO) 
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which  will stimulate the synthesis  of red blood cells. However, the 
diseased kidneys in PKD fail to secrete enough EPO, thus resulting in 
anemia. 
 
CHRONIC  GLOMERULONEPHRITIS:  
Focal glomerulosclerosis and membranoproliferative 
glomerulonephritis are the most likely chronic glomerulonephrities to 
progress quickly in adults. All  hematological   abnormalities  have  been  
noted  in  CKD  due  to  chronic  glomerulonephritis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 
 
44 
 
MATERIALS AND METHODS 
General  
Total no. of patients under study- 150 (50 in each stage 3 -5)  
Period of Study: 
Patients admitted as  inpatients in  the  Department of  Nephrology 
and medicine  at Tirunelveli Medical College Hospital,   during the 
period of  August 2012 - October 2013 were included in this study  of a 
prevalence of hematological  abnormalities in various stages of  CKD . 
 
Geographic distribution: 
Geographic distribution of the patients were predominantly from 
rural areas of  Tirunelveli, Tenkasi, Tuticorin Districts. 
The patients were selected randomly as per  inclusion and  
exclusion  criteria. 
 
Inclusion criteria : 
1. Patients with CKD (Stage 3-5)  
2. Age > 14 years  
 
Exclusion criteria : 
1. Paediatric patients  
2. Pregnant patients  
3. Patients with known hematological disorder  
4. H/O blood transfusion during last 3 months 
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5. Patients with ESRD treated with renal replacement in form of 
dialysis & renal transplantation. 
6. Patients on drugs causing bone marrow suppression.   
 
The  details regarding  age,  sex, weight, monthly income  the 
primary disease leading to CKD, tests  used  in diagnoses-  ultrasound  
abdomen, blood urea, creatinine,  urine- albumin  sugar  and  were 
collected from the case charts. 
 
 Definitions: 
For the purpose of the study, the following definitions were used. 
1) Chronic  kidney disease  defined  as the functional abnormality of 
the kidney manifested   by elevated  serum creatinine  level of 
>1.5mg/dl for more than 3 months. 
2) Anemia in CKD defined as Hb < 13g/dl in men and  in  women  
and <12g/dl. 
3) The estimate of kidney function  was obtained by assessing  eGFR, 
using  cockcroft-gualt  equation. 
 
Cockcroft-Gault equation 
 Estimated creatinine clearance ml/min 
   ! "
#$  %&' (/)
 
 Multiply by 0.85 for women. 
Pcr – Serum Creatinine  
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 INVESTIGATIONS 
1. FIRST LINE OF INVESTIGATIONS: 
 TO  ASSESS  KIDNEY  FUNTION: 
• serum creatinine. 
• blood  urea. 
• urine albumin. 
• urine  sugar. 
• Ultrasound  abdomen. 
2. HEMATOLOGICAL INVESTIGATIONS:   
• Hemoglobin. 
• total count. 
•  differential  count.  
• RBC count, packed cell volume. 
• MCV,  MCH, MCHC. 
• Platelet count. 
• Bleeding time 
• clotting time. 
• Coagulation profile:- 
o prothrombin  time. 
o activated partial  thromboplastin  time. 
o International normalized ratio. 
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• Peripheral  smear study  
 
LABORATORY METHODS :- 
Serum  creatinine  and  urea  was done  on   clotted blood sample  
using  an  automated   biochemical  analyzer –XL-300   based on the 
principle of photometry. serum  creatinine  was  estimated  by  modified  
jaffe method. 
 
Hematological investigations-complete hemogram  which  includes  
total  count, differential count (neutrophils,lymphocytes,eosinophils),  Hb 
,hematocrit,  RBC count, MCV, MCH, MCHC, MCV, Platelet  count, 
were done on EDTA  (Ethylene diamine tetra acetic acid)  blood sample 
on a standardized, quality  controlled and maintained automated cell 
counter -Sysmex KX-21  which analyzes the physiological and chemical 
characteristics of blood cells based on the principles of electric resistance  
detecting method  hydrodynamic focusing method  and flow cytometry 
method  using semiconductor laser. 
 
  Automated  hematology  analyzers  use  the  cyanomethemoglobin  
method to measure the hemoglobin  content of the red blood cell. In this 
method, hemoglobin is converted to cyanated methemoglobin 
(cyanmethemoglobin)  by the addition  of  a  Drabkin solution  which  
contains  potassium ferricyanide and potassium cyanide. Cyanated 
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methemoglobin  maximally absorbs  light at 540 nm, and the total amount 
of hemoglobin is determined by spectrophotometry.  The hemoglobin 
concentration is measured in grams per deciliter (g/dL) of  whole blood. 
The hematocrit   is the ratio of the volume of red blood cells to the 
volume of whole blood. The automated  hematology   analyzer  calculates 
the Hct from the RBC and MCV by the following formula: 
Hct (%) = RBC (cells/L) x MCV  
 
Because  the Hct is a calculated value, it is less accurate than either 
the RBC or Hb, and is affected by errors in either or both of these 
measurements.  
 
The MCV(mean  corpuscular  volume), mean corpuscular 
hemoglobin (MCH), and mean corpuscular hemoglobin concentration 
(MCHC) are the red blood cell indices. The MCH is the  concentration of  
hemoglobin  per cell  (hemoglobin mass/red blood cell), expressed in 
pictograms  per cell (pg, 10-12 g). The MCH is calculated from the 
hemoglobin and RBC by the following formula: 
 
 
The MCH  is decreased in patients with anemia caused by impaired 
hemoglobin synthesis. 
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The MCHC is  the  average  hemoglobin concentration  per  total 
red blood cell volume (ratio of hemoglobin mass to RBC volume), as 
determined from the following equation: 
 
 
The MCHC is decreased in microcytic anemias where the decrease 
in hemoglobin mass exceeds the decrease in the size of the red blood cell.  
 WBC is determined on EDTA-anticoagulated  blood.  RBCs  are 
removed by lysis, and the total WBC is measured by electrical impedance 
or light scatter techniques.  Nucleated red blood cells, unlysed red blood 
cells, platelet clumps, large platelets, and cryoglobulins may result in 
spurious  WBC  results. If these conditions are detected by the 
hematology analyzer, the specimen to be sent for a manual peripheral 
smear evaluation. 
 
• Peripheral smear examination was  done  using  Leishman’s stain. 
• Urine albumin was analysed by manual method using 3% 
sulfosaliclic acid. 
• Urine sugar was analysed  using  benedict  solution.  
• Prothrombin time , activated  partial  thromboplastin  time,  INR  
was  analysed  in automated  analyser  sysmex CA-50. 
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• Serum  protein  was analysed   in  serum  sample  using  automated  
analyser  XL-300. 
 
 Analysis of the laboratory results 
1. Estimated  GFR  levels were categorized into three stages. 
 
STAGE eGFR (ml/min/1.73m2  ) 
3 29-60 
4 15-30 
5 <15 
 
2. Hemoglobin levels were categorized into three group: 
 
 GRADE HB 
MILD ANEMIA 10-12.9 for male, 10-11.9gm/dl for 
female 
MODERATE ANEMIA 7-9.9 gm/dl 
SEVERE ANEMIA LESS THAN 7  gms/dl 
 
3. Blood picture was categorized into: 
• normocytic normochromic, 
• microcytic hypochromic 
• normocytic hypochromic. 
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4. RBC count-   males-4.5-6.5 million / cumm, females-3.8-5.8 million / 
cumm      
5. Hematocrit:-males-40-54    females-37-47 
6. Total count-4000-11000 
7. prothrombin  time:11-16secs 
8. activated  partial  thromboplastin  time:21- 26secs 
9. INR:-1.00- 1.30 
10. platelet  count:-1,50,000-4,50,000  
11. MCV:- 80-96 fl        MCHC:- 32-36g/dl            MCH:-27-32pg 
12. bleeding time - 2.5-9.5 min               
13. clotting time- 3-5 mts 
 
THE RESULTS WERE ANALYZED AS FOLLOWS: 
• 50  patients in  each  stage  of CKD-3,4,5. 
• The number and percentage of each variable with respect to 50 
patients were estimated . 
• RBC count, hemoglobin and peripheral smear, total  count, 
differential count, platelet  count, PT, Aptt, INR were compared 
and correlated with each other. 
 
Statistical Analysis : 
The  details  collected regarding all the selected patients  were 
recorded in a master chart. Data analysis was done with the help of 
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computer by  using SPSS software and Sigma Stat 3.5 version (2012). 
Using the software range, frequencies, percentage, mean, standard 
deviation and ‘p’ value were calculated through One way ANOVA, 
Chi square,  Pearson and Spearman Correlation test and  P value of < 
0.05 has  been  taken as significant. 
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RESULTS  AND  OBSERVATION 
Demography: 
One  hundred  and  fifty patients of CKD  with a  Egfr< 60ml/mt  
were included to study the prevalence of anemia  and  other 
hematological parameters.  
 
There  were  90 males   and 60 females in this study. male  
predominance  was observed.  oldest   male  was a 74 years old. oldest   
female was 70 years. youngest female was 21 years . youngest   male in 
this study  was 25 years. 
 
SEX DISTRIBUTION AND CKD STAGE CORRELATION 
 
Among 90 males  43 were in stage 3 ckd, 11 in stage 4,   36 in stage 5. 
Among 60 females 7 were in stage 3, 39 in stage four, 14 were in stage 5. 
 
 
Sex  CKD  
 Stage 3 Stage 4 Stage 5 
Male 90 43 (86%) 11 (22%) 36 (72%) 
Female  60 7 (14%) 39 (78%) 14 (28%) 
Total 150 50 50 50 
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Above chart shows male predominance in stage 3 and 5 CKD. In 
stage 4 CKD female were predominant.  
 
AGE DISTRIBUTION AND CKD STAGE  CORRELATION 
0
10
20
30
40
50
Stage 3 Stage 4 Stage 5
CKD 
43
11
36
7
39
14
Sex Distribution Vs CKD
Male Female 
Age CKD  
Stage 3 Stage 4 Stage 5 
21-35 0 0 8 (16%) 
36-50 17 (34%) 15 (30%) 19 (38%) 
51-65 29 (58%) 26 (52%) 17 (34%) 
> 65 4 (8%) 9 (18%) 6 (12%) 
Total 50 50 50 
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Maximum   prevalence   was   observed   in  51-65 yr age -group  
in  stage 3 and 4. stage   5  ckd  was  prevalent  in 36-50 age  group.  
younger  age  individuals in the  age- group  of  21-35  tend  to  be  more  
in stage  5  ckd. Individuals   above   65 in this study was 19.among  them 
9 were in stage 4.six  of them in stage 5. Four was in stage 3. 
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 5.2 CLASSIFICATION BASED ON ETIOLOGY: 
 
Etiology CKD  
Stage 
3 
Stage 
4 
Stage 
5 
Total 
HTN 15 8 6 29(19.3%) 
T2DM 12 10 8 30(20%) 
HTN/T2DM 19 26 18 63(42%) 
CGN(FSGS , MPGN, RPGN 
MGN, others) 
3 6 17 26(17.3%) 
ADPKD 1 0 1 2(1.3%) 
Total  50 50 50 150 
(100%) 
 
Diabetes  was  the  leading  cause  of  CKD in this study followed 
by hypertension .63 patients  had both hypertension  and diabetes. 30 
patients  had  only  diabetes. so totally in 93 patients  had diabetes  was   
the  underlying   etiology.   
 
In this  study  29  patients  had  hypertension   . In patients who 
presented with hypertension, it was either primary in etiology or 
secondary to chronic  pyelonephritis.  Among   29,eighteen  patients was 
in stage 3. eight  patients  was stage 4 . only six  was in stage 3…  
                                 
 
57 
 
  Among  the  glomerular disease , membranoproliferative 
glomerulonephritis, rapid  progressive  glomerulonehritis, membranous  
nephropathy ,focal  segmental glomerulonephritis  were found to  be  the 
cause of  ckd in 26 patients. 
 
  Autosomal dominant polycystic  kidney disease  was the etiologic 
factor in  two patients(males).  One patient was in stage 3 other was in 
stage 5. 
 
ANEMIA IN CKD:  
CORRELATION   BETWEEN  HEMOGLOBIN  IN  MALES  AND  
CKD  STAGES 
 
Hb CKD  
Stage 3 Stage 4 Stage 5 Total /  
p value 
<13g/dl No.of cases 16 9 36 61 
mean 12.53 11.06 7.54 (67.8%) <0.001 
sig 
> 13g/dl          26 2 0 29 
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Among   90  males  61  patients had  anemia. 26 were mildly 
anemic, 21 had moderate anemia, 14   were   severely  anemic. mean   hb 
in  stage 3 is 12.53. mean    hb  in stage4  was 11.06. mean   hb  in stage  
5  was 7.54. it  is  evident  that  hb  decreases  as   ckd stage  progressed.  
this   fall is  statistically  significant  with p  value <0.001.  
 
CORRELATION  BETWEEN ANEMIA  IN  FEMALES AND  CKD  
STAGE 
Hb CKD  
Stage 3 Stage 4 Stage 5 Total 
< 12 No. of cases 
Mean 
6 
10.05 
30 
10.27 
14 
5.49 
50 (83.3%) 
< 0.001 Sig 
> 12 No.of cases 1 9 0 10 (16.7%) 
    
 
 Non Anemia Mild 
(10 - 12.9) 
Moderate 
(7.0 - 9.9) 
Severe 
(<7) 
Male  
(90) 
29 26 21 14 
CKD 3 4 5 3 4 5 3 4 5 3 4 5 
27 2 0 16 7 3 0 2 19 0 0 14 
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 Non Anemia Mild 
(10 - 11.9) 
Moderate 
(7.0 - 9.9) 
Severe 
(<7) 
 
Female  
(60) 
10 24 14 12 
CKD 3 4 5 3 4 5 3 4 5 3 4 5 
1 9 0 3 21 0 3 8 3 0 1 11 
 
Among   60  females  about  50  were anemic. 24 had mild anemia, 
14 had  moderate  anemia, 12  had severe anemia. 
 
Mean  hb in stage  3  was 10.05. mean  hb  in  stage  4 ckd  was 
10.49. mean hb  in stage  5 was 5.49. so  it was  evident    that  anemia  
worsens as  ckd  progresses.this fall  is  statistically  significant   with   p 
value  <0.001.  
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 Above  figure  shows that   anemia  is  more  prevalent  in 
females.the  reason  may  be    generally  in south  Indian  females  
anemia is  highly prevalent,when  they develop chronic  kidney  
disease,which  become  an  added  factor, and so  anemia  is  more 
prevalent  in females. 
 
CORRELATION   BETWEEN ANEMIA   IN CKD ITS VARIOUS 
ETIOLOGIES 
 
In   patients with   ckd   and  due to   hypertension, 8  male and 7  
female had anemia.14(13 male,1  female) were not  anemic. 
• In patients were ckd was due  to diabetes,12  male, and 12  
female  had  anemia. 
6(4 male,2 female) was not  anemic. 
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• In  patients  with  both diabetes  and  hypertension,10 males and  
18  females  had  anemia.26(20 male and 6 female)  were  not  
anemic. 
• In  patients  with  chronic  glomerulonephritis, 11  males  and  12 
female  had  anemia. only  2 males  and  one  female  were  not  
anemic. 
 
Etiology Total Male (90) Female (60) 
Anemia Non 
Anemia 
Anemia Non 
Anemia 
HTN 29 8 (27.5%) 13(44.8%) 7(24.13%) 1(3.44%) 
T2DM 30 12 (40%) 4(13.3%) 12(40%) 2(6.66%) 
HTN/T2DM 63 10(15.8%) 29(46.03%) 18(28.57%) 6(9.52%) 
CGN 
 
26 11(42.3%) 2(7.69%) 12(46.15%) 1(3.84%) 
ADPKD 2 1(50%) 1(50%) 0 0 
 
Anemia is  highly prevalent  in  individuals, were  diabetes  and 
chronic  glomerulonephritis were the underlying  etiology  for  CKD. In  
hypertensive  nephrosclerosis,  percentage  of females  with  anemia was 
more. 
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ADPKD  WAS  UNDERLYING  ETIOLOGY  IN 2  MALES: 
        CASE-1     CASE-2 
• Mr.Akbar Ali.                       Mr.Madasamy 
• 53 Yr  old male.                      54 yr male. 
• stage 3 CKD.                       Stage  5 CKD. 
• hb-14.2g/dl.                          Hb-12.9g/dl. 
• RBC count --4.21 lakhs/cumm.           RBC-2.24L/cumm. 
• platelet count --3,21,000.                   Platelet count-2,98,000 
• Peripheral  smear-normal  picture      normal  blood  picture. 
 
Among  2 males, one  had  hb  just below cut-off  value. otherwise  
all  blood  counts  were  normal. 
 
 
28%
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NNA-normocytic  normochromic  anemia, MHA- microcytic  
hypochromic  anemia, NHA-normocytic   hypochromic  anemia. In this  
study  there  was preponderance of  normocytic  normochromic  anemia 
of  36%. Normal  blood  picture was seen in 33% . microcytic  
hypochromic picture was  seen in 12%.next  common picture  was  
normocytic hypochromic which was  10%. Pancytopenia was  seen in 5% 
of individuals.1% of  individuals  showed dimorphic blood  picture. 
Burr cells were  present in  20 patients  irrespective  of peripheral 
smear picture  and  ckd  stage.  
  
          NORMOCYTIC   NORMOCHROMIC BLOOD PICTURE 
 
This  is  the  most  common  type  of   blood  picture  seen  in  
patients  with  anemia  in  ckd. here  mean  corpuscular  volume  is in  
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normal range ( 80-100 ). however  hemoglobin  and  hematocrit  is  
decreased.  It is  anemia  of   chronic  disease. 
 
Reticulocyte count was low < 0.5% in cases with anemia, 
indicating bone marrow suppression and EPO deficiency.    
RBC  COUNT IN CKD :
 
 
RBC count progressively decreased as  ckd  progressed  from stage  3-5. 
 
Stage RBC Mean SD ‘p’ value 
3 3.263 0.734  
< 0.001 
Significant 
4 2.839 0.847 
5 1.387 0.547 
 
3.263
2.839
1.387
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RBC  mean  in  stage  3  was 3.263 ,   with  standard  deviation-
0.734.  
In stage  4  CKD, RBC  mean was  2,839 , with SD- 0.847. 
In  stage 5  CKD,RBC  mean was  1.387, with SD-0.547. Thus  it  
is  this  study RBC  count  progressively  decreased  as  stage  declined. 
This  fall  was  statistically  significant  with  p value <0.001. 
  
LEUKOCYTES IN CKD 
In  this  study total count  progressively  decreased  as CKD  stage  
progressed. Quantitative as well as morphological changes were 
observed. The type of leukocytosis was neutrophilic which was 3%. In 
cases of neutrophilia, neutrophils with hypersegmented nuclei and coarse 
granulation of cytoplasm were common features. History of urinary tract 
infection was present in 2 of them. Eosinophilia was seen in six cases.  
 
CORRELATION BETWEEN TOTAL COUNT AND  CKD STAGE 
Stage TC Mean SD ‘p’ value 
3  7678.4 2425  
< 0.001 
Significant 
4 6941.6 2621 
5 4557.2 3718 
 
Mean   value of  TC  decreases  stage  by  stage.  The  decreases are 
statistically significant (‘p’ value is < 0.001)  
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Mean TC In stage 3 CKD is-7678.4. in stage  4 CKD  mean TC is-
6941.6. in stage 5 CKD, mean was-4557.2. 
 
  PLATELETS’ PROFILE IN CKD: platelet   count   
progressively decreased  as  CKD stage  declined. 
 
PLATELET COUNT   AND  CKD  STAGE CORRELATION 
Platelet Stage 3 Stage 4 Stage 5 
< 1,00,000 0 1 35 
100000  - 150000 2 15 5 
150000 - 450000 48 34 10 
0
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3 4 5
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TC Mean
TC …
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CORRELATION  BETWEEN  PLATELET  COUNT AND   CKD 
STAGE        
Stage Platelet Mean SD ‘p’ value 
3 256460 57800  
< 0.001 
Significant 
4 207938 72930 
5 98640 75472 
 
In stage 3 CKD,  out of 50 patients, 48  had  normal platelet count  
ranging between 1.5 lakhs and 4.5 lakhs.  and 2 patients had mild 
decrease in platelet count ranging between 1 and 1.5 lakhs. 
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Among 50 patients in stage 4 CKD, 34 had normal platelet 
values,15 patients had mild decrease in platelet values ranging  between 1 
to 1.5 lakhs. only  one had thrombocytopenia less than  1 lakh. 
 
Among  50  patients in stage 5  CKD,10 patients  had normal 
count.5 had mild decrease.but 35 patients had thrombocytopenia with 
platelet  less than 1lakh. 
 
This  fall in platelet count  as ckd stage declined was  statiscally 
significant. 
                                    
  BLEEDING   TIME 
 
Stage BT SD ‘p’ value 
3 2.440 1.37  
< 0.001 
Significant 
4 3.240 1.88 
5 5.100 2.61 
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Bleeding time prolonged as ckd   progressed. Mean value increased 
stage by  stage.increase was statistically  significant (p 
value<0.001).normal  bleeding  time is 1-7 minutes.  
 
CORRELATION  BETWEEN CLOTTING TIME  AND  CKD 
STAGE 
Stage CT SD ‘p’ value 
3 4.04 1.29  
< 0.001 
Significant 
4 4.60 1.94 
5 6.58 2.77 
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In study  clotting  time  slightly prolonged  as  CKD progressed. 
Increase was statiscally significant. ( p value-<0.001). 
 
COAGUALATION PROFILE: 
PROTHROMBIN TIME: 
Stage PT SD ‘p’ value 
3 12.96 1.18  
< 0.001 
Significant 
4 13.31 1.49 
5 16.03 2.48 
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Normal  prothrombin  time  is 11-16 seconds. In this  study  it was  
found that  prothrombin  time  tends  to  prolong  as  CKD  stage  declines 
in stage 3 CKD  mean was 12.96. In stage 4 CKD, mean was 13.31 .in 
stage 5 CKD,mean was16.03. prolongation  of  PT was  stastically 
significant. 
 
ACTIVATED   PARTIAL   THROMBOPLASTIN  TIME: 
APTT Stage 3 Stage 4 Stage 5 
< 21 0 0 3 
21 – 28 46 46 11 
> 28 4 4 36 
Total 50 50 50 
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Stage APTT SD ‘p’ value 
3 24.56 2.259  
 < 0.001 
Significant 
4 25.216 2.646 
5 30.358 5.567 
 
In our  study,  APTT  prolongs   as  CKD stage declines. From 
table is evident that 46 individuals in stage  3 and 4 ckd  had normal  
APTT. Only four patients had prolonged APTT. But  in stage 5 CKD  
thirty six patients  had  prolonged   APTT. Mean   APTT   in  stage 3  was 
24.56. 
 
In stage 4   mean  APTT  was  25.21.  In stage 5  mean APTT was 
30.35 prolongation  was  statiscally  significant.(p value<0.001). 
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 INTERNATIONAL  NORMALISED  RATIO:  
 
 
 
 
In  this  study  INR  tends to prolong as  ckd  stage declined mean 
INR in stage 3 was1.362. mean INR in stage 4 was 1.34. mean INR  in  
stage 5  was 1.596. 
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DISCUSSION 
Prevalence and risk factors: 
Chronic  kidney  disease  has  been a  major  public  health  
problem  and  a major cause of morbidity and mortality  worldwide. The 
actual prevalence of  the initial stages of CKD is much more than the later 
stages. 
 
Coresh J et al have reported a prevalence of   3.3%, 3.0%, 4.3%, 
0.2% and 0.2% respectively in stages 1, 2, 3, 4, 5 of CKD 8. 
 
However in clinical practice prevalence of  stages 4 and 5 appears 
to be more because initial stages are asymptomatic and people  present  
themselves when  severity of symptoms increases. 
 
This study included 150 patients with a diagnosis of CKD which 
was based on the estimated  gfr  levels.  50 in each  stage3-5. 
 
The prevalence is probably high compared to the western literature, 
as the patients seek treatment only at later stages when the severity of 
symptoms increases. Economic  constraints also play a role. 
 
 Coresh J et al and Viswanathan et al have indicated that the 
prevalence of   CKD is higher in older age groups with a male 
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preponderance. The former  has also  reported that 11% of individuals  
older  than 65 years have CKD8.  
 
The present study also  showed  predominance  in  older  age,  the 
maximum number  of   cases in  stage 3 and 4 was in the age group 51 -
65years. Cases  in stage  5  was  maximum  in 36-50  age  group. The 
older age  and the male predominance can be explained by the underlying  
disease  entity causing  CKD. Diabetes and hypertension, both of which 
are etiological factors of CKD are  prevalent  more  in  older  age  group  
and  male  sex8. 
 
CKD is a progressive condition and its progression is influenced by 
the  underlying  kidney  disease leading to CKD and the presence of risk 
factors2.  
 
Among   the  etiology  of  CKD , as per the DOQI advisory board  
guidelines, diabetes is the most common cause followed by hypertension, 
vascular diseases, glomerular diseases, cystic diseases and 
tubulointerstitial diseases28. 
 
Diabetes and hypertension are both etiological and risk factors. 
Comparison of the prevalence rates of etiologic disease of this study with 
that of  DOQI guidelines has shown a similar trend,diabetes as leading 
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cause followed by hypertension, glomerular diseases and others. 63 cases 
had both diabetes and hypertension.  
 
  All  hematological abnormalities  were  prevalent  irrespective  of  
the  underlying  etiology  causing  the  CKD. Anemia  was   highly 
prevalent  in  patients , were  diabetes  and chronic  glomerulonephritis  
were the underlying  cause  for  CKD. In  hypertensive  nephrosclerosis,  
percentage  of females  with  anemia was higher. 
 
  Hematological profile:Evaluation  of anemia  in chronic kidney 
disease begins with general clinical evaluation  to assess both the possible 
causes and the clinical impact of  anemia. Measures used to assess 
anemia and its causes include  hemoglobin , hematocrit  and  peripheral  
smear. 
 
Hemoglobin as an index of anemia Hemoglobin concentration is 
used  as  primary parameter  because it  can be directly measured for 
which there is an international standard and is not influenced by 
differences in technology. Hence this is a accepted parameter and so used 
as a baseline investigation in this study. In addition, for a patient to be  
repeated  as and when required, this  investigation   is  financially viable. 
The cut off value of the Hb level for the  diagnosis of anemia in CKD is 
13g/dl  for  males  and 12g/dl  for females as per  WHO  criteria  and  
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further  anemia  has  been graded  as  mild, moderate  and  severe  
anemia.   KDOQI   cut  off  values  not  taken  into account  since anemia  
is  not  graded in it. 
 
  In  the  present   study, among  males  67.8%  had  anemia.  83.3%   
of  females  had  anemia. So  it  evident  that  females  are  more  anemic  
than  males. majority  had  mild  anemia  and  very   few had  severe  
anemia.  
 
  But   progressive  decline  in  haemoglobin  concentration,  PCV 
and  total red cell count was noted   among  our subjects as the disease 
progressed. This can be   explained by a corresponding  reduction in the 
synthesis  and  serum levels of  erythropoietin which is a major drive for 
erythropoiesis in the bone marrow.  Other factors may contribute to this 
in our subjects especially the associated  malnutrition. 
 
Hb levels decreased , indicating that the severity of anemia  
increased  parallelly  with the increase  in the severity of CKD. The study 
done by Callen IR et al showed that anemia becomes more severe as 
CKD progresses34.This is because, as CKD progresses, inhibition of bone 
marrow, deficiency of  EPO, deficiency of  iron  and  bleeding tendencies 
increase as a result of an increase in the circulating uremic toxins. 
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Normocytic   normochromic   blood picture was the most common 
in the study  with  36%, followed by microcytic  hypochromic which  was 
12%.  then normocytic hypochromic picture  which was 10%.This is also 
the scenario reported in the study by Callen IR et al 34 and in the study by 
the DOQI advisory board33 
 
The MCV, MCH, MCHC  of  the patients with a normocytic  
picture  were normal.   RBC count  also progressively decreased  as  CKD  
stage declined . reduced   erythropoietin  production is the principal  
factor responsible for the anemia  in CKD. EPO deficiency leads to a 
decreased production of normal RBCs, the extent of which depends upon 
the extent of EPO deficiency. 
 
Maximum  Hb  in study  was  15g/dl. He  was  54 yr old male,  
who  had  both  diabetes  and hypertension. In  our  study  patient  with 
Autosomal dominant polycystic kidney disease  also  had  high  Hb   of 
14.3g/dl. ADPKD  is  known  to  be  associated  with high Hb levels4. 
The patient  was  in stage 3 CKD. The patient  was neither on dialysis nor 
on  recombinant  erythropoietin, which rules out the beneficiary effect of 
these. One of the patients had hypertension, which is also known to be 
associated with high Hb levels. 
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Microcytic hypochromic picture was seen in 12 % of cases. This is 
because of the presence of combination of  factors leading to anemia. 5  
patients  had motion  occult  blood  positive, which  may  be  due  to  
occult  gastrointestinal  bleeding.  among  them 4 had microcytic 
hypochromic  anemia,0ne  patient  had  normocytic  hypochromic  
anemia.  Associated  iron deficiency  would be  the cause in them. 
 
 In patients with chronic kidney disease there are three primary 
disturbances that predispose to the development of iron deficiency as 
summarized below: 
1. Increased external iron losses 
              Blood retention by the hemodialysis filters and lines 
              Frequent blood sampling for laboratory testing 
             Occult gastrointestinal bleeding 
             Accidental blood loss from the hemodialysis access 
2. Sequestering of iron in storage tissues with decreased availability for 
erthropoiesis. 
3. Decreased  iron absorption Functional iron deficiency is a state in 
which iron is present in sufficient  quantity in storage tissues with 
inefficient access to iron by erythroid precursors. In  such a state there 
will be   increased iron stores in  bone  marrow biopsy  and  associated 
increased serum ferritin levels. Given the chronic  inflammatory state 
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in CKD, the increase in serum ferritin could be as an acute phase  
reactant. But  transferrin saturation level will be abnormal indicating 
the low level of iron available for erythropoiesis. 
 
Some of the peripheral  smears showed  elliptocytes,  ovalocytes,  
and target cells. Seven  patients showed  pancytopenia.2  patients  showed  
dimorphic anemia. 20  smears showed presence of  burr cells. Burr cells 
are known to be associated with anemia in CKD. Burr cells  also called as 
crenated cells  which show an uneven distribution of  spicules  on their  
surface . Burr cells  characteristically  occur  in uremia, where they 
represent  damaged or fragmented red blood cell. 
 
Abnormalities in white cells and platelets 
Certain morphological and quantitative alterations were noted with 
leukocytes.40  patients  showed  leucopenia with total  count  less than 
4000/cumm. In this study total  count  decreased  as  CKD stage declined. 
EPO is known to stimulate erythropoiesis  with little effect on 
granulopoiesis41. A fall in the leucocyte count  may be due to suppression 
of  granulopoiesis  because  of  erythropoietin  deficiency.  sequestration 
of neutrophils within the dialyser and in the lungs can  also  be  an 
possibility, although studies with labeled cells show that they later return  
to circulation. . 5  patients  in this  study showed leukocytosis-reactive  
neutrophilia. 2  of  them  had clinical evidence of infection  mainly  UTI. 
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It  is also possible that leukocytosis is a response to infection. It is 
possible that infections are due to impaired leukocyte function  though   
they are  increased in number 5.  
 
In our study  platelet  count  declined  as    progressed . EPO 
deficiency is a possibility as EPO is known to stimulate 
megakaryocytopoiesis to some extent41.  
 
HEMOSTATIC  ABNORMALITIES: 
In  this  study  bleeding  time  and clotting  time  prolonged  as  ckd  stage  
declined, indicating  uremia  is  prone  for  abnormalities  in  hemostasis.  
Also  prothrombin  time , APTT, INR  tends to  prolong  as  ckd stage 
declined. 
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CONCLUSIONS 
• CKD is prevalent in adult population with a male predominance in 
older age 51-65 groups. 
• Diabetes and hypertension are the commonest etiological factors of 
CKD. 
• Anemia is a common complication of CKD  and the degree  of  
anemia increases as CKD worsens. 
•  Mild  anemia with normocytic  normochromic  picture with sparse 
distribution of RBCs is the most common picture. 
• Anemia  prevalence  was higher  in  females. 
• Etiological correlation -  anemia  and  other  hematological   
abnormalities  were  prevalent, irrespective  of  the  underlying  
etiology  causing  the  CKD. 
• Leucophenia was observed, which worsened as CKD progressed.  
• Thrombocytopenia  is  observed   which  worsened  as CKD  
progressed. 
• Both bleeding and thrombotic tendencies were observed as CKD 
worsened. 
• Chronic kidney disease patients have lower haematological indices 
and the degree of changes depends on the severity of chronic 
kidney disease. 
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LIST OF ABBRVIATIONS USED (in alphabetical order) 
APTT    Activated Partial Thromboplastin Time 
BT                                               Bleeding Time 
CKD                                           Chronic Kidney Disease 
CGN     Chronic Glomerulonephritis    
DOQI                                          Dialysis Outcome Quality Initiative 
EGFR                                          Estimated Glomerular Filtration Rate 
ESRD                                         End Stage Renal Disease 
EPO                                            Erthropoeitin 
FSGS                                          Focal Segmental Glomerulonephritis 
GFR                                            Glomerular  Filtration  Rate 
Hb                                               Hemoglobin 
HCT                                            Hematocrit 
HTN     Hypertension  
INR     International Normalized Ratio  
MDRD                                        Modification  of  Diet  In  Renal  disease 
MCV                                           Mean  Corpuscular  Volume 
MCH                                           Mean  Corpuscular  Hemoglobin 
MCHC                                        Mean Corpuscular Hemoglobin Concentration 
MPGN    Membrano Proliferative Glomerulonephritis 
MGN     Membranous Glomerulonephritis 
SCR                                            Serum Creatinine 
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PROFORMA 
NAME: 
AGE:                        SEX:               
OCCUPATION:                                                                              
MONTHLY INCOME:  
HISTORY OF DIABETUS MELLITUS: 
HISTORY OF HYPERTENSION: 
ETILOGY: 
WEIGHT: 
 
1) INVESTIGATIONS FOR ASSESSMENT OF RENAL FUNCTION: 
A) BLOOD UREA: 
B) SERUM CREATININE: 
C) URINE ALBUMIN:  
D) URINE SUGAR: 
E) ULTRASOUND ABDOMEN: 
 
2) INVESTIGATIONS FOR ASSESSMENT OF HEMATOLOGICAL 
CHANGES: 
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A)COMPLETE  BLOOD  COUNT: 
Total 
count 
Differential 
count 
Hb hematocrit MCV MCH MCHC Platelet 
count 
        
               
B) MOTION OCCULT BLOOD: 
C) SERUM ALBUMIN: 
D) PERIPHERAL SMEAR STUDY: 
E) RETICULOCYTE PERCENTAGE: 
F) COAGULATION PROFILE: 
           BLEEDING TIME: 
           CLOTTING TIME: 
 prothrombin time Activated  partial  
thromboplastin time 
Control value 
Reference  value 
  
TEST  VALUE   
 
INTERNATIONAL NORMALISED RATIO: 
ESTIMATED  GLOMERULAR  FILTRATION  RATE :  
 
